Garnett Timothy John 4

What Happened
Timothy J. Garnett, a director of MapLight Therapeutics, acquired 14,124 shares in an open-market purchase on February 10, 2026. The reported weighted-average price was $17.89 per share for a total value of $252,678. This was a purchase (buy) rather than a sale or option exercise.

Key Details

• Transaction date: 2026-02-10; Form 4 filed: 2026-02-12 (timely filing).
• Shares purchased: 14,124; reported weighted-average price: $17.89; total reported value: $252,678.
• Price range: purchases occurred at prices from $17.76 to $17.90 (footnote F1 — weighted avg reported; breakdown available on request).
• Shares are held by the "Timothy J Garnett Revocable Trust Dated U/A 09/22/2021"; Garnett is sole trustee with voting and dispositive power (footnote F2).
• The filing did not disclose the total number of shares owned by Garnett after this transaction in the information provided here.

Context
This was an open-market buy (not an option exercise, gift, or 10b5-1 sale plan). Purchases by insiders can be of interest to investors as one data point on insider sentiment, but the filing itself does not state Garnett’s motivations.